Düsseldorf, Germany – A recent case report from Germany highlights the potential of blinatumomab, a cancer therapy, in treating refractory generalized myasthenia gravis (gMG)— a form of the autoimmune disease that does not respond to standard treatments. Two women with severe, treatment-resistant MG experienced marked clinical improvements following treatment with...
Latest News
San Antonio, Texas – A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB). Scientists at Texas Biomedical Research Institute (Texas Biomed) found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant. The findings, reported in the journal...
ATLANTA – Cancer Treatment Centers of America® (CTCA) Atlanta has launched its Women’s Cancer Center, led by an experienced roster of fellowship-trained, board-certified physicians and clinicians with expertise in breast and gynecologic oncology. The center offers comprehensive cancer care – from screenings, diagnostic evaluations and treatment plans to supportive care...
Kyoto, Japan — An old campaign slogan for cough syrup, “It tastes awful. And it works,” seemed to imply that any sweet content might have diminished the medicinal effect. Sweetness, in the case of cancer, appears as a chain of sugar molecules attached to proteins by beta1,4-galactosyltransferase-3, or B4GALT3 According...
Lehi, Utah — CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, reported that CEO Ryan Davies discussed the future of the cancer therapeutic industry with Dr. Looper, a life-long researcher in the chemistry field. Ryan Looper, Ph.D., Colorado State...
Santa Barbara, Calif. — CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that its UCLA research team has created a promising new drug candidate for treating recurrent Ewing sarcoma, a deadly children’s cancer. Ewing sarcoma is a rare...
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the presentation of updated data from an ongoing phase 1b clinical trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110,...
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This...
NEEDHAM, Mass. — Candel Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of...
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced encouraging interim data from its ongoing phase 1b clinical trial of CAN-3110 (linoserpaturev) in recurrent glioblastoma, and a publication in the...